Who is sponsoring NCT00826891?

NCT00826891 is sponsored by Chinese Anti-Cancer Association.

What condition does NCT00826891 study?

NCT00826891 studies Cervical Cancer.

What drugs are being tested in NCT00826891?

Interventions: Cisplatin Combined With Topotecan.

What is the status of NCT00826891?

NCT00826891 is currently UNKNOWN.

Last reviewed 2009-01-20 · How we verify

Phase II Study of Cisplatin Combined With Topotecan in Advanced (Stage IVB) Recurrent or Persistent Cervical Cancer

NCT00826891 Phase 2 UNKNOWN

This is a single arm, open-label study in women from China who have Advanced (stage IVB) Recurrent or Persistent cervical cancer to ⑴assess the response rate (i.e., CR + PR) of Cisplatin combined with Topotecan in treatment of advanced (stage IVB) recurrent or persistent Cervical cancer; ⑵assess the toxicities of CT regimen in treatment of cervical cancer. Prior to treatment, written informed consent should be obtained from all patients. Eligible patients will be assigned to CT regimen. The CT regimen is topotecan 0.75 mg/m2 IV during 30minutes days 1, 2, and 3; followed by cisplatin 50 mg/m2 IV on day1, repeated every 21 days. The study will consist of two phases: the safety run-in phase and study phase.

Details

Lead sponsor	Chinese Anti-Cancer Association
Phase	Phase 2
Status	UNKNOWN
Enrolment	40
Start date	2009-02
Completion	2010-01

Conditions

Cervical Cancer

Interventions

Cisplatin Combined With Topotecan

Primary outcomes

Response rate (CR + PR) (RECIST) — 4~6 weeks after the end of treatment